A single arm clinical study to evaluate the efficacy of the Vitamin C in improving skin brightness and enhancing overall skin parameters

UAS Pharmaceuticals Pty Ltd1 个研究点分布在 1 个国家目标入组 32 人开始时间: 2025年10月6日最近更新: 2025年9月23日

试验速览

阶段: Unknown
状态: 尚未招募
发起方: UAS Pharmaceuticals Pty Ltd
入组人数: 32
试验地点: 1
主要终点: 1. change in Skin Gloss

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

An open label one arm study.

Each participant entering the trial will be assigned to a regimen of investigational product with the below assessments.

Product to be applied at face and neck both.

Skin Gloss by Glossymeter (T0, day 14 and day 28 )
Skin Pigmentation by Mexameter Face (Melanin Index) (Day 0, 14, 28)
Skin Hydration by Corneometer (T0, day14 and day 28)
Dark Spots by Visioface (Day 0, 14, 28)
Skin Barrier by TEWAMETER (Day 0,14,28)
Dermat evaluation on a 5-point ordinal scale would be used for the Even Skin Tone (Day 0, 14,28)
Dermat evaluation on a 5-point ordinal scale would be used for the Skin Texture (Day 0, 14,28)
Dermat evaluation on a 5-point ordinal scale would be used for the Smooth skin (Day 0, 14,28)
Visioscan Images( Day 0 and Day 28)
HD Imaging with DSLR (Day 0 and Day 28 )
Subject’s Self Assessments. (day 28 )

Subjects will be on study for up to 28 days. Screening & Assigning: Day 0 Follow-ups: on Day 0 and Day 14 EOT: Day 28

Test Product: Neutriderm Vitamin C Serum Dose: Gently use approx. 5-6 drops of the Vitamin C serum on the face twice a day for 4 weeks. Route of Administration: Topical

研究设计

研究类型: Observational

入排标准

年龄范围: 18.00 Year(s) 至 45.00 Year(s)（—）

入选标准

•Gender: Male or Female with age 18-45 2) Subjects with mild pigmented skin.
•Subjects willing to give written informed consent 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry.
•Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events.
•Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

排除标准

•Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study.
•Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition.
•Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product.
•Have participated in any interventional clinical trial in the previous 90 days.
•Have a known sensitivity to any of the constituents of the test product
•Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids.
•Have not skin related issues.